PABLO
ROJO CONEJO
Profesor titular de universidad
University of the Witwatersrand
Johannesburgo, SudáfricaPublications in collaboration with researchers from University of the Witwatersrand (13)
2023
-
Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile
Pediatric Research, Vol. 94, Núm. 5, pp. 1667-1674
-
Genomic investigations of unexplained acute hepatitis in children
Nature, Vol. 617, Núm. 7961, pp. 564-573
-
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
eClinicalMedicine, Vol. 60
2022
-
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 9, pp. e627-e637
-
Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries
Frontiers in Pediatrics, Vol. 10
-
Machine learning outperformed logistic regression classification even with limit sample size: A model to predict pediatric HIV mortality and clinical progression to AIDS
PloS one, Vol. 17, Núm. 10, pp. e0276116
-
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648
-
Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence
BMC public health, Vol. 22, Núm. 1, pp. 1312
2021
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543
2020
-
The HIV drug optimization agenda: promoting standards for earlier investigation and approvals of antiretroviral drugs for use in adolescents living with HIV
Journal of the International AIDS Society
2018
-
Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in European perinatally HIV-infected children
Journal of Acquired Immune Deficiency Syndromes
-
Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation
Journal of the International AIDS Society, Vol. 21, Núm. 11
-
The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis
PLoS Medicine, Vol. 15, Núm. 3